Wang Z, Zhang RY, Ji C, Zhang JY, Yue BT, Wang F. Revolutionizing gastrointestinal cancer research with artificial intelligence: From precision patient stratification to real-world evidence. World J Gastrointest Oncol 2025; 17(10): 111339 [PMID: 41114095 DOI: 10.4251/wjgo.v17.i10.111339]
Corresponding Author of This Article
Feng Wang, MD, PhD, Professor, Senior Researcher, Senior Scientist, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, No. 50 Eastern Jianshe Road, Zhengzhou 450052, Henan Province, China. zzuwangfeng@zzu.edu.cn
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Oct 15, 2025 (publication date) through Oct 26, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Wang Z, Zhang RY, Ji C, Zhang JY, Yue BT, Wang F. Revolutionizing gastrointestinal cancer research with artificial intelligence: From precision patient stratification to real-world evidence. World J Gastrointest Oncol 2025; 17(10): 111339 [PMID: 41114095 DOI: 10.4251/wjgo.v17.i10.111339]
World J Gastrointest Oncol. Oct 15, 2025; 17(10): 111339 Published online Oct 15, 2025. doi: 10.4251/wjgo.v17.i10.111339
Revolutionizing gastrointestinal cancer research with artificial intelligence: From precision patient stratification to real-world evidence
Zhe Wang, Rui-Ying Zhang, Cheng Ji, Jia-Yi Zhang, Bing-Tong Yue, Feng Wang
Zhe Wang, Rui-Ying Zhang, Feng Wang, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
Cheng Ji, Department of Clinical Medicine, North Henan Medical University, Xinxiang 455000, Henan Province, China
Jia-Yi Zhang, Bing-Tong Yue, Department of Clinical Medicine, The First Clinical Medical College of Zhengzhou University, Zhengzhou 45000, Henan Province, China
Co-first authors: Zhe Wang and Rui-Ying Zhang.
Author contributions: Wang Z and Zhang RY contributed equally to this work as co-first authors; Zhang JY and Wang F conceived and supervised the study and made critical revisions; Yue BT and Ji C performed the literature search and assisted in data organization; Wang Z drafted the original manuscript; all authors contributed to manuscript preparation and approved the final version for submission.
Conflict-of-interest statement: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Feng Wang, MD, PhD, Professor, Senior Researcher, Senior Scientist, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, No. 50 Eastern Jianshe Road, Zhengzhou 450052, Henan Province, China. zzuwangfeng@zzu.edu.cn
Received: July 1, 2025 Revised: July 28, 2025 Accepted: August 27, 2025 Published online: October 15, 2025 Processing time: 108 Days and 23 Hours
Abstract
Gastrointestinal (GI) cancers exact a staggering global toll through high incidence, mortality, and treatment costs, yet clinical research continues to be hampered by inadequate patient stratification, challenging recruitment, suboptimal adherence, and time-consuming endpoint confirmations. Against this backdrop, artificial intelligence (AI) emerges as a powerful game-changer, offering streamlined trial design, predictive enrollment matching, dynamic endpoint assessment, and real-world data integration. This review synthesizes AI-driven advancements across the GI cancer research continuum. It covers precise patient stratification, automated efficacy evaluations, and remote compliance management. The analysis also addresses persistent challenges in data standardization, privacy protection, and regulatory oversight. We underscore the need for synergistic clinician–AI collaboration, alongside robust frameworks that ensure interpretability and ethical deployment. By illuminating the potential of AI to accelerate trial timelines, refine patient selection, and enhance outcome measurement, we aim to inspire new strategies that can significantly reduce the global burden of GI malignancies. Ultimately, this work provides a blueprint for stakeholders seeking to harness AI’s transformative capabilities, fostering a future in which GI cancer clinical research becomes more agile, personalized, and impactful for patients and healthcare systems alike.
Core Tip: Artificial intelligence (AI) is reshaping gastrointestinal cancer research by improving patient stratification, streamlining clinical trial design, and enabling real-world data integration. This review highlights how AI can accelerate trial timelines, enhance precision, and support remote monitoring, while also addressing key challenges in data standardization and ethical implementation.
